Current state of hematopoietic cell transplantation in CLL as smart therapies emerge

Mohamed A. Kharfan-Dabaja, Jessica El-Asmar, Farrukh T. Awan, Mehdi Hamadani, Ernesto Ayala

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Novel therapies targeting various kinases downstream of the B-cell receptor have emerged along with monoclonal antibodies and BCL-2 antagonists, and are changing the therapeutic landscape of chronic lymphocytic leukemia. However, cure remains unattainable unless eligible patients are offered an allogeneic hematopoietic cell transplant. Access to allogeneic hematopoietic cell transplantation has expanded considerably with availability of reduced intensity conditioning regimens which is capable offering durable remissions even in poor-risk disease. Encouraging data from ibrutinib and venetoclax in Del17p is challenging the notion of disease eradication as the ultimate therapeutic goal to a new concept of merely disease control. By favoring the non-transplant approach, patients should be aware that there are no established salvage therapies, yet, to rescue disease progression after ibrutinib. When disease eradication is the desirable approach, a reduced intensity conditioning allogeneic hematopoietic cell transplant is the preferred choice at this time.

Original languageEnglish (US)
Pages (from-to)54-66
Number of pages13
JournalBest Practice and Research: Clinical Haematology
Volume29
Issue number1
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Keywords

  • Allogeneic hematopoietic cell transplantation
  • B-cell receptor inhibitors
  • Reduced intensity conditioning

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Current state of hematopoietic cell transplantation in CLL as smart therapies emerge'. Together they form a unique fingerprint.

  • Cite this